7/102 sources · 2 publishersUpdated Oct 27, 15:12 UTC
Argus downgrades Abbott Laboratories to Hold after cutting full‑year guidance
Argus Research lowered its rating on Abbott Laboratories (ABT) from Buy to Hold, citing the company's reduced full‑year revenue growth outlook. The downgrade follows Abbott's cut to its 2026 full‑year revenue guidance to about 6% and a narrowed adjusted earnings‑per‑share range of $5.50‑$5.55. The firm also noted uncertainty around Abbott's planned spin‑off of its Nutrition business by the end of 2027.
Why it matters
The downgrade prompted analysts to lower price targets, with BTIG cutting its target to $125 and Mizuho to $115, which could pressure the stock price in the near term.
Key facts
- 1Argus downgraded Abbott Laboratories to Hold from Buy. investing.com
- 2Abbott cut its full‑year 2026 revenue guidance to approximately 6%, down from the prior 6.5%‑7.5% range. investing.com
- 3Adjusted earnings per share for Q3 2026 were $1.42, matching Wall Street estimates. investing.com
- 4Quarterly revenue was $13.01 billion, with sales rising 7% year over year. investing.com
- 5Adjusted EPS guidance for the full year was narrowed to $5.50‑$5.55. investing.com
- 6Abbott plans to spin off its Nutrition business by the end of 2027. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.